Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia

被引:238
作者
Hammarsten, J [1 ]
Högstedt, B
机构
[1] Varberg Hosp, Dept Surg, Urol Sect, S-43281 Varberg, Sweden
[2] Cent Hosp, Dept Occupat Med, Halmstad, Sweden
关键词
benign prostatic hyperplasia; dyslipidaemia; hyperinsulinaemia; hypertension; metabolic syndrome; non-insulin-dependent diabetes mellitus; obesity;
D O I
10.1159/000052430
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the validity coefficient of the total prostate gland volume as an expression of the transition zone (TZ) volume. To test the hypothesis of hyperinsulinaemia as a causal factor for the development of benign prostatic hyperplasia (BPH). Patients and Methods: Three hundred and seven consecutive patients with lower urinary tract symptoms were studied. A subgroup of 114 patients were tested with regard to the validity coefficient between the total prostate gland volume and the TZ volume. In the total material of 307 men, a BPH risk factor analysis was performed in which groups of men with the following conditions were related to the annual BPH growth rate: men without or with metabolic disease; men with different components of the metabolic syndrome, and men with low or high fasting plasma insulin values. The prostate gland volume and the TZ volume were determined using ultrasound. The presence of non-insulin-dependent diabetes mellitus (NIDDM) and treated hypertension was obtained from the patients' medical records. Data on blood pressure, waist and hip measurement, body height and weight were collected and body mass index and waist/hip ratio were calculated. Blood samples were drawn from fasting patients to determine the insulin and HDL-cholesterol values. Results: In the subgroup of men subjected to measurement of both the total prostate gland volume and the TZ volume, the correlation coefficient between total prostate gland volume and the TZ volume was r.s. =0.97 (p<0.0001) which, thus, constituted the validity coefficient. The median annual BPH growth rate in the total group was 1.03 ml/year. The median annual BPH growth rate was faster in men with metabolic disease (p<0.0001), NIDDM (p<0.0001), treated hypertension (p<0.0001), obesity (p<0.0001) and dyslipidaemia (p<0.0001) than in men without metabolic disease. Moreover, the annual BPH growth rate correlated positively with the diastolic blood pressure (r.s. = 0.27; p<0.001), the BMI (r.s. = 0.22; p<0.001) and four other expressions of obesity, and negatively with the HDL-cholesterol level (r.s. = -0.15; p<0.001). The methan annual BPH growth rate was faster in men with a high than in men with a low fasting plasma insulin level (p = 0.019). When the patients were divided into quartiles, the median annual BPH growth rate increased statistically significantly with increasing fasting plasma insulin levels. The fasting plasma insulin values correlated with the annual BPH growth rates (p = 0.009). When performing a multivariate analysis using the total prostate gland volume as dependent variable, fasting plasma insulin (p = 0.001) and age (p<0.001) became statistically significant. Conclusion: The results of the present report suggest that the total prostate gland volume constitutes a valid expression of BPH. The findings support the hypothesis that hyperinsulinaemia is causally related to the development of BPH and generate the hypothesis of an increased sympathetic nerve activity in men with BPH. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:151 / 158
页数:8
相关论文
共 58 条
[11]   COMPARATIVE-STUDY OF PLASMA STEROID AND STEROID GLUCURONIDE LEVELS IN NORMAL MEN AND IN MEN WITH BENIGN PROSTATIC HYPERPLASIA [J].
BROCHU, M ;
BELANGER, A .
PROSTATE, 1987, 11 (01) :33-40
[12]   α1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia [J].
Chon, JK ;
Borkowski, A ;
Partin, AW ;
Isaacs, JT ;
Jacobs, SC ;
Kyprianou, N .
JOURNAL OF UROLOGY, 1999, 161 (06) :2002-2008
[13]   EFFECT OF PHYSICAL-TRAINING ON INSULIN ACTION IN OBESITY [J].
DEFRONZO, RA ;
SHERWIN, RS ;
KRAEMER, N .
DIABETES, 1987, 36 (12) :1379-1385
[14]   INSULIN RESISTANCE - A MULTIFACETED SYNDROME RESPONSIBLE FOR NIDDM, OBESITY, HYPERTENSION, DYSLIPIDEMIA, AND ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE [J].
DEFRONZO, RA ;
FERRANNINI, E .
DIABETES CARE, 1991, 14 (03) :173-194
[15]   PLASMA STEROIDS IN BENIGN PROSTATIC HYPERTROPHY AND CARCINOMA OF THE PROSTATE [J].
DRAFTA, D ;
PROCA, E ;
ZAMFIR, V ;
SCHINDLER, AE ;
NEACSU, E ;
STROE, E .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1982, 17 (06) :689-693
[16]   PREVENTION OF TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES-MELLITUS BY DIET AND PHYSICAL EXERCISE - THE 6-YEAR MALMO FEASIBILITY STUDY [J].
ERIKSSON, KF ;
LINDGARDE, F .
DIABETOLOGIA, 1991, 34 (12) :891-898
[17]   SYMPATHONEURAL AND HEMODYNAMIC CHARACTERISTICS OF YOUNG SUBJECTS WITH MILD ESSENTIAL-HYPERTENSION [J].
FLORAS, JS ;
HARA, K .
JOURNAL OF HYPERTENSION, 1993, 11 (06) :647-655
[18]   NATURAL-HISTORY OF PROSTATISM - RELATIONSHIP AMONG SYMPTOMS, PROSTATE VOLUME AND PEAK URINARY FLOW-RATE [J].
GIRMAN, CJ ;
JACOBSEN, SJ ;
GUESS, HA ;
OESTERLING, JE ;
CHUTE, CG ;
PANSER, LA ;
LIEBER, MM .
JOURNAL OF UROLOGY, 1995, 153 (05) :1510-1515
[19]   SYMPATHETIC ACTIVATION IN OBESE NORMOTENSIVE SUBJECTS [J].
GRASSI, G ;
SERAVALLE, G ;
CATTANEO, BM ;
BOLLA, GB ;
LANFRANCHI, A ;
COLOMBO, M ;
GIANNATTASIO, C ;
BRUNANI, A ;
CAVAGNINI, F ;
MANCIA, G .
HYPERTENSION, 1995, 25 (04) :560-563
[20]   BENIGN PROSTATIC HYPERPLASIA - ANTECEDENTS AND NATURAL-HISTORY [J].
GUESS, HA .
EPIDEMIOLOGIC REVIEWS, 1992, 14 :131-153